EGFR and neoplasm: Although CAR T cells are compelling preclinically, translation is limited by individualized manufacturing, on-target/off-tumor toxicities (e.g., with epidermal growth factor receptor (EGFR)-directed products), and premature T-cell exhaustion 13.